Viz.ai has announced a multi-year collaboration with global healthcare company Sanofi and biotechnology firm Regeneron to support the management of chronic obstructive pulmonary disease (COPD) using artificial intelligence (AI).

Viz.ai 宣布与全球医疗保健公司赛诺菲和生物技术公司再生元达成多年合作，利用人工智能 (AI) 支持慢性阻塞性肺疾病 (COPD) 的管理。

COPD is a long-term lung condition that causes breathing difficulties and affects around 392 million people globally. It is currently the fourth leading cause of death worldwide. The condition places a heavy burden on healthcare systems, especially when cases are not managed effectively. Many patients receive suboptimal care due to delays in identifying risk levels, poor care coordination, limited monitoring, and barriers to treatment..

慢性阻塞性肺病（COPD）是一种长期的肺部疾病，会导致呼吸困难，全球约有3.92亿人受其影响。它是目前全球第四大死亡原因。该疾病给医疗系统带来了沉重负担，尤其是在病例未得到有效管理时。由于风险水平识别延迟、护理协调不佳、监测有限以及治疗障碍，许多患者未能获得最佳护理。

The partnership will focus on evaluating an AI-powered care coordination tool designed to improve detection and treatment for patients with high-risk COPD.

该合作伙伴关系将专注于评估一种由人工智能驱动的护理协调工具，该工具旨在改善高危慢性阻塞性肺疾病患者的检测和治疗。

As part of the collaboration, Viz.ai will deploy its COPD module, a digital solution that uses electronic health record (EHR) data and AI to identify patients in need of timely intervention. The technology is intended to assist healthcare providers in streamlining workflows, enabling faster and more efficient care..

作为合作的一部分，Viz.ai 将部署其 COPD 模块，这是一种利用电子健康记录 (EHR) 数据和人工智能来识别需要及时干预的患者的数字解决方案。该技术旨在帮助医疗保健提供者简化工作流程，实现更快、更高效的护理。

The Viz COPD module applies natural language processing to review patient records, helping to screen and prioritise individuals according to clinical guidelines. High-risk cases are flagged for follow-up, aiming to ensure patients receive the care they need sooner. This solution builds on Viz.ai’s existing reach, which includes more than 1,700 hospitals and health systems and over 60,000 healthcare providers..

Viz COPD模块利用自然语言处理技术审查患者记录，帮助根据临床指南筛查和优先排序个体。高风险病例会被标记以进行后续跟进，旨在确保患者能够更快获得所需的护理。该解决方案基于Viz.ai现有的覆盖范围，已涵盖超过1700家医院和卫生系统，以及超过60,000名医疗保健提供者。

Through this partnership, Viz.ai, Sanofi, and Regeneron aim to address gaps in COPD care by advancing the use of AI to support earlier intervention and improve outcomes for patients living with this serious respiratory disease.

通过这一合作，Viz.ai、赛诺菲和再生元旨在通过推进人工智能的使用来弥补COPD护理中的不足，支持更早的干预，并改善患有这种严重呼吸系统疾病患者的结果。